Press/Media
- 1 - 25 out of 137 results
Search results
-
Findings in Fabry Disease Reported from Charles University and General University Hospital Prague (Safety and efficacy of pegunigalsidase alfa in patients with Fabry disease who were previously treated with agalsidase alfa: results from BRIDGE, ...)
11/8/23
1 item of Media coverage
Press/Media: Research
-
Weekly: Anatara Lifesciences (ANR: 2.80c) trading at high volume
6/12/23
1 item of Media coverage
Press/Media: Research
-
Monthly: Anatara Lifesciences (ANR: 2.80c) trails 94% of stocks
4/3/23
1 item of Media coverage
Press/Media: Research
-
Researchers at University Health Network Publish New Study Findings on Gene Therapy (Persistent hematopoietic polyclonality after lentivirus-mediated gene therapy for Fabry disease)
3/7/23
1 item of Media coverage
Press/Media: Research
-
CHRISTUS St. Michael to break ground March 28 on emergency center
3/3/23
1 item of Media coverage
Press/Media: Research
-
Weekly: Anatara Lifesciences (ANR: 3.0c) shares post worst week in sixteen weeks; -0.4c [11.8%]
2/28/23
1 item of Media coverage
Press/Media: Research
-
Weekly: Anatara Lifesciences (ANR: 3.0c) shares post worst week in sixteen weeks; -0.4c [11.8%]
2/25/23
1 item of Media coverage
Press/Media: Research
-
CHRISTUS St. Michael to break ground March 28 on emergency center
2/25/23
1 item of Media coverage
Press/Media: Research
-
Weekly: Anatara Lifesciences (ANR: 3.40c) surges 6.2% on weak volume; +0.2c [6.2%]
2/21/23
1 item of Media coverage
Press/Media: Research
-
Monthly: Anatara Lifesciences (ANR: 3.80c) rises 27% on high volatility in January 2023
1/31/23
1 item of Media coverage
Press/Media: Research
-
Monthly: Anatara Lifesciences (ANR: 3.80c) rises 27% on high volatility in January 2023
1/31/23
1 item of Media coverage
Press/Media: Research
-
Q4/2022: Monthly: Anatara Lifesciences (ANR: 3.40c) in bottom 4% performers of Australian market in past quarter
12/30/22
1 item of Media coverage
Press/Media: Research
-
Q4/2022: Monthly: Anatara Lifesciences (ANR: 3.40c) in bottom 4% performers of Australian market in past quarter
12/30/22
1 item of Media coverage
Press/Media: Research
-
African Studies Association to Host Annual Meeting Sessions for Nov. 19 (Part 10 of 13)
11/2/22
1 item of Media coverage
Press/Media: Research
-
Monthly: Anatara Lifesciences (ANR: 3.90c) in bottom 2% performers of Australian market in October 2022
11/1/22
1 item of Media coverage
Press/Media: Research
-
Borderline personality features and altered social feedback processing in emerging adults: An EEG study.
10/3/22
1 item of Media coverage
Press/Media: Research
-
Weekly: Anatara Lifesciences (ANR: 6.0c) plummets 7.7% - trailing 84% of stocks
8/6/22
1 item of Media coverage
Press/Media: Research
-
Monthly: Anatara Lifesciences (ANR: 6.50c) up 23% on weak volume in July 2022
7/29/22
1 item of Media coverage
Press/Media: Research
-
Weekly: Anatara Lifesciences (ANR: 6.50c) jumps 4.8% on low volume
7/23/22
1 item of Media coverage
Press/Media: Research
-
Monthly: Anatara Lifesciences (ANR: 5.50c) falls a second month, trailing 88% of stocks
6/30/22
1 item of Media coverage
Press/Media: Research
-
Weekly: Anatara Lifesciences (ANR: 5.90c) increases 1.7% on thin volume
6/25/22
1 item of Media coverage
Press/Media: Research
-
Weekly: Anatara Lifesciences (ANR: 5.80c) falls 1.7% on high volume
6/18/22
1 item of Media coverage
Press/Media: Research
-
Weekly: Anatara Lifesciences (ANR: 5.90c) falls 1.7% on average volume
6/11/22
1 item of Media coverage
Press/Media: Research
-
Q1/2022: Monthly: Anatara Lifesciences (ANR: 9.10c) in bottom 7% performers of Australian market in past quarter
3/31/22
1 item of Media coverage
Press/Media: Research
-